Shandong Sito Bio-technology Co., Ltd. (SHE:300583)
China · Delayed Price · Currency is CNY 14.85
-0.08 (-0.54%)
Feb 13, 2026, 3:04 PM CST
SHE:300583 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 902.37 | 918.22 | 1,225 | 1,242 | 1,174 | 806.9 |
Other Revenue | 52.38 | 52.38 | 54.57 | 70.11 | 28.37 | 106.29 |
| 954.76 | 970.6 | 1,280 | 1,312 | 1,203 | 913.19 | |
Revenue Growth (YoY) | -14.88% | -24.16% | -2.46% | 9.10% | 31.70% | -5.45% |
Cost of Revenue | 954.65 | 862.5 | 1,011 | 1,051 | 956.55 | 814.07 |
Gross Profit | 0.11 | 108.1 | 268.31 | 261.44 | 246.07 | 99.12 |
Selling, General & Admin | 104.52 | 133.14 | 139.84 | 126.18 | 119.54 | 134.46 |
Research & Development | 49.24 | 58.38 | 55.08 | 50.21 | 49.73 | 45.01 |
Other Operating Expenses | 8.45 | 8.66 | 6.21 | 12.08 | 8.11 | 7.74 |
Operating Expenses | 173.68 | 199.7 | 206.48 | 188.81 | 183.29 | 182.6 |
Operating Income | -173.57 | -91.6 | 61.84 | 72.64 | 62.78 | -83.48 |
Interest Expense | -29.74 | -30.85 | -37.66 | -36.89 | -30.21 | -33.98 |
Interest & Investment Income | 7.46 | 14.76 | 8.35 | 11.71 | 6.63 | 10.71 |
Currency Exchange Gain (Loss) | -0.13 | -0.13 | -1.79 | 0.06 | -0.63 | -0.79 |
Other Non Operating Income (Expenses) | -1.27 | -3.67 | -2.55 | -2 | -1.36 | -1.57 |
EBT Excluding Unusual Items | -197.24 | -111.49 | 28.19 | 45.53 | 37.2 | -109.1 |
Impairment of Goodwill | - | - | - | - | - | -53.23 |
Gain (Loss) on Sale of Assets | -0.33 | 0.06 | 0.14 | -0.11 | 0.09 | 0.18 |
Asset Writedown | -9.27 | -0.02 | -0.44 | -0.62 | - | -34.87 |
Other Unusual Items | 8.16 | 8.71 | 25.6 | 3.11 | 17 | 4.57 |
Pretax Income | -198.68 | -102.75 | 53.48 | 47.91 | 54.29 | -192.45 |
Income Tax Expense | -5.03 | -1.42 | 4.93 | 5.45 | 18.5 | -2.83 |
Earnings From Continuing Operations | -193.66 | -101.33 | 48.55 | 42.47 | 35.79 | -189.62 |
Minority Interest in Earnings | 20.95 | 12.56 | -2.94 | -0.5 | 0.42 | 9.81 |
Net Income | -172.71 | -88.77 | 45.6 | 41.97 | 36.21 | -179.81 |
Net Income to Common | -172.71 | -88.77 | 45.6 | 41.97 | 36.21 | -179.81 |
Net Income Growth | - | - | 8.67% | 15.92% | - | - |
Shares Outstanding (Basic) | 195 | 189 | 182 | 175 | 170 | 171 |
Shares Outstanding (Diluted) | 195 | 189 | 182 | 175 | 170 | 171 |
Shares Change (YoY) | 11.92% | 3.54% | 4.32% | 2.63% | -0.51% | 0.62% |
EPS (Basic) | -0.89 | -0.47 | 0.25 | 0.24 | 0.21 | -1.05 |
EPS (Diluted) | -0.89 | -0.47 | 0.25 | 0.24 | 0.21 | -1.05 |
EPS Growth | - | - | 4.17% | 12.94% | - | - |
Free Cash Flow | 66.44 | 128.93 | -186.9 | 1.66 | -161.57 | 12 |
Free Cash Flow Per Share | 0.34 | 0.68 | -1.02 | 0.01 | -0.95 | 0.07 |
Dividend Per Share | 0.020 | 0.010 | 0.450 | 0.009 | 0.009 | - |
Dividend Growth | -95.56% | -97.78% | 4687.23% | - | - | - |
Gross Margin | 0.01% | 11.14% | 20.96% | 19.93% | 20.46% | 10.85% |
Operating Margin | -18.18% | -9.44% | 4.83% | 5.54% | 5.22% | -9.14% |
Profit Margin | -18.09% | -9.15% | 3.56% | 3.20% | 3.01% | -19.69% |
Free Cash Flow Margin | 6.96% | 13.28% | -14.60% | 0.13% | -13.44% | 1.31% |
EBITDA | -3.77 | 78.1 | 231.41 | 233.47 | 196.02 | 59.39 |
EBITDA Margin | -0.40% | 8.05% | 18.08% | 17.79% | 16.30% | 6.50% |
D&A For EBITDA | 169.8 | 169.7 | 169.57 | 160.84 | 133.25 | 142.87 |
EBIT | -173.57 | -91.6 | 61.84 | 72.64 | 62.78 | -83.48 |
EBIT Margin | -18.18% | -9.44% | 4.83% | 5.54% | 5.22% | -9.14% |
Effective Tax Rate | - | - | 9.22% | 11.37% | 34.08% | - |
Revenue as Reported | 954.76 | 970.6 | 1,280 | 1,312 | 1,203 | 913.19 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.